Spatial Genomics and Transcriptomics Market Report 2026

The spatial genomics and transcriptomics market size has grown rapidly in recent years. It will grow from $1.7 billion in 2025 to $1.91 billion in 2026 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to advances in genomics, transcriptomics research growth, oncology biomarker discovery, sequencing cost reduction, research funding.

The spatial genomics and transcriptomics market size is expected to see rapid growth in the next few years. It will grow to $3.02 billion in 2030 at a compound annual growth rate (CAGR) of 12.1%. The growth in the forecast period can be attributed to personalized oncology demand, drug discovery applications, single-cell analysis growth, computational biology expansion, clinical translation focus. Major trends in the forecast period include growth of spatial mapping technologies, integration of ai analytics, rising oncology research adoption, expansion of academic collaborations, increased pharma investment.

The growing adoption of personalized medicine is expected to drive the growth of the spatial genomics and transcriptomics market in the coming years. Personalized medicine is a healthcare approach that customizes treatment plans for individual patients based on their genetic makeup, lifestyle, and environmental factors, aiming to improve treatment efficacy and reduce side effects. Demand for personalized medicine is rising due to advances in genetic research, which enable more precise treatments tailored to an individual’s unique genetic profile, resulting in better patient outcomes. Spatial genomics and transcriptomics support personalized medicine by providing detailed insights into the location and activity of genes within tissues, allowing for targeted, individualized treatment strategies based on a patient’s molecular landscape. For example, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, a notable increase from six approvals in 2022. Therefore, the rising adoption of personalized medicine is fueling the growth of the spatial genomics and transcriptomics market.

Key companies in the spatial genomics and transcriptomics market are focusing on developing innovative solutions, such as spatial transcriptomics technologies, to advance the understanding of gene expression within tissue architecture. Spatial transcriptomics technologies are advanced methods that map gene expression across tissue samples while maintaining spatial context, enabling researchers to study the location and distribution of RNA molecules within tissues. For instance, in February 2025, Illumina Inc., a US-based biotechnology company, introduced a pioneering spatial transcriptomics technology that significantly enhances the ability to map and analyze gene expression within complex tissues at cellular resolution. Offering a capture area nine times larger and four times higher resolution than previous methods, it enables unbiased, whole-transcriptome profiling with high sensitivity. Compatible with Illumina’s NextSeq and NovaSeq sequencers and integrated into the Illumina Connected Multiomics platform, this technology supports comprehensive multiomic data analysis.

In April 2024, Bruker Corporation, a US-based manufacturer of scientific instruments and analytical solutions, acquired NanoString Technologies for an undisclosed amount. Through this acquisition, Bruker aims to strengthen its spatial biology portfolio with complementary gene expression and spatial transcriptomics solutions, positioning the company as a market leader while driving innovation, revenue growth, and long-term value in the post-genomic era. NanoString Technologies is a US-based biotechnology company providing both spatial genomics and spatial transcriptomics solutions.

Major companies operating in the spatial genomics and transcriptomics market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Agilent Technologies Inc., Illumina Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Bio-Techne Corporation, 10x Genomics Inc., Standard BioTools Inc., Akoya Biosciences Inc., Seven Bridges Genomics, Vizgen Inc., Lunaphore Technologies SA., Parse Biosciences, Indica Labs Inc., Resolve Biosciences GmbH., RareCyte Inc., Ionpath Inc., Dovetail Genomics, S2 Genomics Inc., BioSpyder Technologies Inc.

North America was the largest region in the spatial genomics and transcriptomics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spatial genomics and transcriptomics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the spatial genomics and transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs in the spatial genomics and transcriptomics market by raising prices for imported sequencing platforms, imaging systems, reagents, and microfluidic consumables. Research institutes, CROs, and pharmaceutical companies in Asia-Pacific and Europe are most affected due to reliance on advanced international technologies. These higher costs can slow adoption in precision medicine and drug discovery. However, tariffs are encouraging regional production of reagents and analytical software, strengthening long-term market resilience.

The spatial genomics and transcriptomics market research report is one of a series of new reports that provides spatial genomics and transcriptomics market statistics, including spatial genomics and transcriptomics industry global market size, regional shares, competitors with a spatial genomics and transcriptomics market share, detailed spatial genomics and transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the spatial genomics and transcriptomics industry. This spatial genomics and transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Spatial genomics and transcriptomics are techniques that map the spatial arrangement of gene expression and genetic information within tissues, enabling researchers to study how cells interact in their native environment and contribute to various biological processes or diseases. These methods provide a high-resolution, detailed view of gene activity in specific tissue locations, offering insights into cellular heterogeneity, disease mechanisms, and potential therapeutic targets.

The main types of products in spatial genomics and transcriptomics include instruments, consumables, and software. Instruments are devices or tools used for scientific purposes, encompassing both experimental and theoretical research. They include technologies such as spatial transcriptomics, sequencing-based methods, immunohistochemistry (IHC), microscopy-based RNA imaging techniques, and spatial genomics. These instruments support a range of applications, including diagnostics, translational research, drug discovery and development, single-cell analysis, cell biology, and more. They are utilized by pharmaceutical and biotechnology companies, contract research organizations, and academic and research institutions.

The spatial genomics and transcriptomics market includes revenues earned by entities by providing services such as spatial gene expression profiling, single-cell RNA sequencing, spatially resolved transcriptome analysis, cancer and disease research, and spatial epigenomics. The market value includes the value of related goods sold by the service provider or included within the service offering. The spatial genomics and transcriptomics market also includes sales of spatial transcriptomics platforms, imaging systems, and sequencing instruments. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.